Work

Phase II trial to evaluate immune-related biomarkers for pathological response in stage II-III HER2-positive breast cancer receiving neoadjuvant chemotherapy with subsequent randomization to multi-epitope HER2 vaccine versus placebo in patients with residual disease post-neoadjuvant chemotherapy.

Year: 2022

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2022.40.16_suppl.tps610

Authors: Saranya Chumsri, Nadine Norton, Sarah Bruggeman, David W. Hillman, Brenda Ernst, Kathryn Jean Ruddy, Donald W. Northfelt, Pooja Prem Advani, Kostandinos Sideras, Alvaro Moreno-Aspitia, Matthew P. Goetz, Keith L. Knutson

Institutions: Mayo Clinic in Florida, Mayo Clinic, Mayo Clinic Hospital, Mayo Clinic Comprehensive Cancer Center (Minnesota), Erasmus MC

Language: English

Topic: HER2/EGFR in Cancer Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: U.S. Department of Defense

OpenAlex ID: W4281765899

Cites:

Cited by: 5

Related to: 10